09:24 AM EDT, 07/18/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Friday said Health Canada accepted its New Drug Submission for CREXONT, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.

"The submission of CREXONT in Canada highlights Knight's ongoing commitment to enhancing our central nervous system portfolio," said Chief Executive Samira Sakhia.

Shares of the company closed up $0.15 to $6.21 on Thursday on the Toronto Stock Exchange.